Global /South Korea /Healthcare /Drug Manufacturers - General /382150

Oncocross Co., Ltd.

382150

• KRX: 382150 • Delayed

8,500KRW -6%

5.63 USD

As of 18 June 2026, Oncocross Co., Ltd. has a market cap of $73.04M USD, ranking #27860 globally and #1452 in South Korea. It ranks #2519 in the Healthcare sector, and #905 in the Drug Manufacturers - General industry.

Global Rank

27860

Country Rank

1452

Sector Rank

2519

Industry Rank

905

Key Stats

Market Cap

$73.04MUSD

110.25B KRW

Enterprise Value

$61.07MUSD

92.18B KRW

Revenue (TTM)

$245.44KUSD

370.46M KRW

EBITDA (TTM)

-$5.31MUSD

-8.02B KRW

Net Income (TTM)

-$5.92MUSD

-8.93B KRW

PS Ratio

297.6

PB Ratio

8.2

Company Profile

Country (HQ)

South Korea

Sector

Healthcare

Industry

Drug Manufacturers - General

Founded

2015

Website

oncocross.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
-6%	2.8%	34%	-4.4%	9.8%	-5.6%	-29%	-61%	-61%

News

Markets

Exchange	Ticker	Price	Quotes
Korea Exchange (KRX) MIC: XKRX PRIMARY	382150 주식회사 온코크로스 ISIN: KR7382150001 Shares Out.: Shares Outstanding: 12.196M¹ Shares Float: 8.604M² TV: TradingView: KRX: 382150 SA: Stock Analysis: KRX: 382150 YF: Yahoo Finance: 382150.KS GF: Google Finance: KRX: 382150 BA: Barron's: 382150 MS: Morningstar: XKRX: 382150	8,500 KRW	TV: TradingView: KRX: 382150 SA: Stock Analysis: KRX: 382150 YF: Yahoo Finance: 382150.KS GF: Google Finance: KRX: 382150 BA: Barron's: 382150 MS: Morningstar: XKRX: 382150

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Oncocross Co., Ltd.

Oncocross Co., Ltd. develops drugs for the treatment of cancers, rare diseases, and intractable diseases in South Korea. Its products pipeline includes OC101 for liver cirrhosis; OC101+OC111 for non-alcoholic steatohepatitis; OC201+OC202e for Inhibition of cancer metastasis; OC211, a Pan-KRAS Inhibitor; OC221, an immuno-oncology combination; OC514 to treat amyotrophic lateral sclerosis and Duchenne muscular dystrophy; and OC701 to treat atopic dermatitis. The company is also developing OJP3101 for metabolic disease; OJP3101 for Cardiovascular Disease; ODP9401 for metabolic disease; and ODP2201, ODP2301, and ODP2401 to treat oncology-related diseases. It has a collaboration agreement with various pharmaceutical companies, research institutes, and bio-techs. The company was founded in 2015 and is based in Seoul, South Korea.

Similar Companies

Industry: Drug Manufacturers - General (South Korea)

Name	Market Cap (USD) diff.	PE	Country
Samsung Epis Holdings Co., Ltd. KRX: 0126Z0	$9.22B 13.91T KRW 13K%	-	South Korea
Sam Chun Dang Pharm. Co., Ltd. KRX: 000250	$6.83B 10.3T KRW 9K%	1958.1	South Korea
SK Biopharmaceuticals Co., Ltd. KRX: 326030	$5.28B 7.97T KRW 7K%	29.9	South Korea
ABL Bio Inc. KRX: 298380	$5.0B 7.55T KRW 7K%	-	South Korea
Yuhan Corp. KRX: 000100	$4.58B 6.92T KRW 6K%	35.9	South Korea
LigaChem Biosciences Inc. KRX: 141080	$4.48B 6.76T KRW 6K%	-	South Korea

Industry: Drug Manufacturers - General (Global)

Name	Market Cap (USD) diff.	PE	Country
Eli Lilly and Co. NYSE: LLY	$761.68B 1M%	38.1	United States
Johnson & Johnson NYSE: JNJ	$547.28B 749K%	26.4	United States
AbbVie Inc. NYSE: ABBV	$360.63B 494K%	97.4	United States
Roche Holding AG SIX: RO	$323.08B 256.25B CHF 442K%	19.9	Switzerland
AstraZeneca PLC LSE: AZN	$289.5B 215.59B GBP 396K%	27.6	United Kingdom
Novartis AG SIX: NOVN	$275.99B 218.9B CHF 378K%	20.5	Switzerland

chevron_leftBack